104 results about "Human pancreas" patented technology

Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.

A human glucagon associated peptide-2 analog Pro-Pro-h[Gly2]GLP-2(1-35) for treating the short bowel syndrome and malabsorption of stomach and intestine is prepared through configuring genetic engineering bacterium for effective expression of Pro- Pro-h[Gly2]GLP-2(1-35) in colibacillus cell, splitting, washing, dissolving urea, depositing in alcohol, separating fusion protein, hydrolyzing it, chromatography by DEAE-52 column, separating by HPLC, and freeze drying.

The invention relates to methods for generating insulin secreting cells from precursor stem cells or from adult pancreatic exocrine cells. The methods of the invention are useful, for example, for generation of glucose sensitive insulin-secreting beta-cells suitable for transplantation, as well as for in situ development of insulin-secreting cells in a patient in need thereof. Further, the method of the invention relates to methods for preventing premature differentiation of precursor stem cells into insulin-secreting beta-cells. Still further, the invention relates to assay methods for identification of compounds that prevent or activate beta-cell differentiation.

The invention provides a veratramine degradation product veratrum fluorene aldehyde 1 and derivatives thereof. The invention uses steroidal alkaloid veratramine (A) as raw material and prepares veratrum fluorene aldehyde by oxidative degradation of m-chloroperoxybenzoic acid to obtain 20 derivative compounds of the veratrum fluorene aldehyde 1 after further oxidation, reduction and condensation reaction. The 20 compounds of the invention have good inhibitory activity on cancer cells, wherein the compounds 1, 2, 5, 8, 13 and 17 have good inhibitory activity on cells of human pancreatic cancer cells BxPC-3 and SW1990, small-cell lung cancer cells NCI-H446, human colorectal cancer LOVO and the like, and the inhibitory activity of the compound veratrum fluorene aldehyde 1 is the most significant.

The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a / Arf, Ink4a, Arf, p53, Smad4 / Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents.

The invention discloses a method for separation and in-vitro culture of pancreatic cancer tissue organs of human. The method comprises the following steps that (1) after the pancreatic cancer tissue of human is cut, enzymic digestion is repeatedly carried out for 10-20 minutes at 37 DEG C in a rotation speed of 30-40 rpm three times, and a pancreatic cancer single cell is obtained; (2) the pancreatic cancer single cell and matrigel are uniformly mixed, then a culture medium containing a growth factor PEG2 and gastrin I are added for culture, and the pancreatic cancer tissue organs of human areobtained. The method for separation and in-vitro culture of the pancreatic cancer tissue organs of human has the advantages that the tumor tissue is digested by adopting a short-time repeated digestion method, which can effectively improve the cell yield and cell viability; the culture medium containing the growth factor PEG2 and the gastrin I is adopted for culture, which can effectively promotethe growth of the pancreatic cancer organs and increase the survival rate of the pancreatic cancer organs.

The present invention relates to a gene engineered bacteria, and its preparation method and uses, belongs to biological engineering field. The gene engineered bacteria is composed of plasmid and host bacteria in which host bacteria is any one of Ecoli DH5alpha,BL21(DE3) or Rosetta-gami(DE3), the recombinant plasmid is pET32a(+) containing gene GAD65. The construction method of engineered bacteria comprise: designing Nest-PCR upper-stream primer and down-stream primer, amplifying human GAD65 gene fragment using PCR from human pancreas cDNA library, transforming Ecoli via vector and obtaining highly effective expression recombinant human GAD65 gene engineered bacteria. The inventive engineered bacteria can be used to produce soluble active thioredoxin- human Glutamic Decarboxylase 65 fusion protein and active recombinant human GAD65 which has enzymatic activity and immunological activity and are easy to purify. The expression volume is high and cost is low .

The invention discloses microencapsulated human pancreatic carcinoma cells, and a preparation method and application thereof. The preparation method comprises the following steps of: adding suspension with human pancreatic carcinoma cells into Matrigel-containing sodium alginate solution; spraying into a calcium chloride solution in high voltage electrostatic environment to obtain microspheres; and performing ion exchange reaction on the microspheres and a sodium citrate solution, and thus obtaining the microencapsulated human pancreatic carcinoma cells. The obtained microencapsulated human pancreatic carcinoma cells have uniform size and the diameter of about 420mm. Cells in microcapsules are well proliferated, and grow in a three-dimensional way. The microencapsulated human pancreatic carcinoma cells are applied to subcutaneous tumor and in-situ tumor animal models, and have the advantages of high modeling success rate and quick tumor growth compared with the traditional tumor cell suspension injection method.

The present invention relates to one kind of recombinant kallidinogenase and its preparation process. The recombinant kallidinogenase is produced by means of molecular biological technology and with host cell for expressing recombinant protein, and is purified through an affinity chromatographic process. It has several clinical uses and less side effects.

The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (PANEC-1 and PANEC-2) from human pancreas cells. The present invention also provides for antisense molecules to the nucleotide sequences which encode PANEC-1 and PANEC-2, expression vectors for the production of purified PANEC-1 and PANEC-2, antibodies capable of binding specifically to PANEC-1 and PANEC-2, hybridization probes or oligonucleotides for the detection of PANEC-1- or PANEC-2-encoding nucleotide sequences, genetically engineered host cells for the expression of PANEC-1 and PANEC-2, diagnostic tests for chemokine activation based on PANEC-1- and PANEC-2-encoding nucleic acid molecules and antibodies capable of binding specifically to the protein.

The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice.

The invention relates to a novel human pancreatic cancer nude mouse model construction method for living imaging research and a use thereof. A human pancreatic cancer PANC-1 cell is stably transfected with a plasmid carrying a luc gene through a Lonza nuclear transfection system, a cell strain PANC-1-LUC for stable luciferase expression is screened through puromycin and PANC-1-LUC nude mouse transplant subcutaneous sarcoma is further constructed. An in vitro and vivo bioluminescence detection result proves that the PANC-1-LUC cell strain can stably express luciferase for a long time. Compared with a lentiviral vector-mediated bioluminescence pancreatic cancer nude mouse model, the built pancreatic cancer nude mouse model has a short tumor formation incubation period and a high tumor formation rate, satisfies PANC-1 transplantation tumor growth features and is suitable for living imaging research.

The invention provides jervine steroid alkaloid derivatives. Steroidal alkaloids, namely veratramine, jervine and cyclopamine are taken as raw materials, and subjected to chemical modification to obtain ninety-three derivatives, which comprise N-hydrocarbon and N-acylate. In the invention, cell lines such as human pancreatic cancer cells B*PC-3 and SW1990, a small cell lung cancer cell NCI-H466, a non-small cell lung cancer cell NCI-H157 and the like are selected, the antitumor activity of all compounds are evaluated by an MTT method, and results show that the derivatives 41, 43 and 58 have obvious antitumor activity, the other eight derivatives 10, 18, 19, 38, 45, 48, 50 and 92 also show medium antitumor activity, and the derivatives can be used for preparing antitumor medicaments.

The invention relates to the technical field of Chinese traditional medicine preparation, in particular to cinobufagin injection effective component and new use of the effective component in preparation of antineoplastic drug. The invention uses macroporous absorbent resin to separate effective components from cinobufagin injection; water and 50% ethanol are then respectively to use for eluting components of various polarities separated by HP-20 macroporous absorbent resin; the components are then analyzed and distinguished by thin layer chromatography and high performance liquid chromatography to prepare non-polarity components of cinobufagin injection with lipophilic phrynin lactone substances and polarity components of water-soluble alkaloid substances. In vivo and in vitro anti-tumor tests of the cinobufagin injection effective component has proven that the cinobufagin injection effective component can inhibit SW1990 auxesis; the cinobufagin injection effective component has obvious inhibiting effect to tumor growth of nude mice loaded with human pancreatic cancer which can be used for further preparation of anti-human pancreatic cancer drug, in particular for preparation of anti-human pancreatic cancer drug which comprises non-polarity components of cinobufagin injection.

The invention discloses a pancreas cancer prevention use of polycyclic fused macrocyclic lactam compounds. The structural formula of the polycyclic fused macrocyclic lactam compounds is shown in the description; and in the formula, R1 is OCH3 or H, R2 is Cl or OH, and R3 is OCH3 or H. The polycyclic fused macrocyclic lactam compounds are separated through separating and purifying a fermentation liquid of Streptomyces xiamenensis CGMCC No.4.3534 from mangrove soil. Prepared ikarugamycin and derivatives thereof can inhibit proliferation and vitality of human pancreas cancer cells, and can be used to prepare pancreas cancer prevention drugs.

The present invention relates to variant AAV capsid polypeptides, wherein the variant AAV capsid polypeptides exhibit increased transduction and / or tropism in human pancreatic tissue or human islets as compared non-variant parent capsid polypeptides.

The present invention provides mammalian pancreatic progenitor cells (“small cells”) and methods for their isolation and propagation. The pancreatic small cells are derived from adult pancreatic tissue and are characterised by their small size. The small cells are quiescent or undergo a very slow cell cycle when maintained in cell culture. Small cells secrete synaptophysin and islet hormones and are predominantly found in small, growing islets as small clusters. The present invention further provides for the use of the pancreatic small cells in transplantation and the treatment of diabetes mellitus, and for the genetic engineering of the small cells in order to produce recombinant proteins in vivo.

The invention relates to a mithramycin nano-particle suspension and a preparation method thereof. The preparation method comprises the following steps: preparation of a diblock copolymer solution; preparation of an organic phase of mithramycin; preparation of an emulsifier solution; mixing and aftertreatment; etc. A mithramycin nano-particle prepared in the invention can retain the pharmacological activity of mithramycin; materials used in the invention are biocompatible materials, so the mithramycin nano-particle has the characteristic of application security and has good application prospect; meanwhile, the mithramycin nano-particle can be effectively enriched in the part of a transplanted tumor of a naked mouse and presents substantial treatment effect on transplanted tumors of human pancreatic cancer cells BxPC-3 in naked mice.

Fresh human pancreas tissue can be used as a source of cells whence to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.

The invention relates to the technical field of biological medicine, and concretely relates to a construction method of a human pancreatic cancer tissue organoid model. The method comprises the following steps: S1, washing a fresh human pancreatic cancer specimen with a cleaning solution, and mechanically cutting into pieces; S2, carrying out enzyme digestion on the mechanically cut tissue fragments; S3, carrying out enzyme-free digestion on the tissue fragments subjected to enzyme digestion, collecting supernatant, and centrifuging to obtain pancreatic cancer single cell precipitate; and S4, fully and uniformly mixing the pancreatic cancer single cells obtained in the step S3 with a matrix material, inoculating gel drops, and adding the gel drops into a complete culture medium for culture. The same pancreatic cancer specimen is sequentially treated by adopting mechanical shearing, enzyme digestion and non-enzyme digestion, and single cells and cell masses with excellent organoid yield are separated, so that the utilization rate of the pancreatic cancer specimen is increased, the quantity and activity of inoculated pancreatic cancer cells are ensured, the number of the organoids meeting the requirement of high-throughput clinical drug screening can be obtained within a short culture time, and a solid foundation is laid for clinical transformation of the organoids.

The invention discloses a process for preparing human pancreas secretion type trypsin Inhibitor through eucaryon secretory expression method comprising, (1) synthesizing human pancreas secretion type trypsin inhibitor genes possessing engineering bacterium codon preferring property and constructing expression vectors, (2) constructing and fermenting engineering bacterium, (3) preparing and purifying recombinant human pancreas secretion type trypsin Inhibitor preparations.

The invention discloses a construction method of a pancreatic duct epithelial cell and pancreatic acinar cell co-culture system for simulating in vivo microenvironment, and belongs to the technical field of cell biology. The method comprises the steps of inoculating an upper layer of a Transwell dual-layer culturing chamber with original generation pancreatic acinar cells, inoculating a lower layer of the Transwell dual-layer culturing chamber with human pancreatic duct epithelial cells, performing co-culturing, adding sodium taurocholate in the pancreatic duct epithelial cells at the lower layer of the Transwell dual-layer culturing chamber, and observing the vitality, the shape and the apoptosis of the upper layer pancreatic acinar cells. Damage of the pancreatic duct epithelial cells and the pancreatic acinar cells are combined, a non-contact type co-culture manner is adopted for building the pancreatic duct epithelial cell and pancreatic acinar cell co-culture system. In the co-culture system, the two cells can exchange exocytosis secretion substances through Transwell transmembrane. The system can well simulate the pancreatitis induced by cholestasis, and the invention provides an in vitro cell model which can really reflect pancreatitis induced by cholestasis.

The invention discloses application of a 12H-indazole [2, 1-a] cinnoline-12-ketone compound, and application of the 12H-indazole [2, 1-a] cinnoline-12-ketone compound and pharmaceutically acceptable salts or hydrates of the compound in preparing drugs for treating malignant tumors. The compound has good inhibitory activity especially on PC-3 cells of human prostate cancer and PANC-1 cells of humanpancreatic cancer, can inhibit the proliferation of the above cancer cells in a dose-dependent manner, and has great application prospects.

Fresh human pancreas tissue can be used as a source of cells whence to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage.

The invention relates to a superparamagnetic iron oxide labeled human pancreas cancer cell strain, wherein superparamagnetic iron oxide is contained in a cell. In a method for labeling the human pancreas cancer cell strain through the superparamagnetic iron oxide, polylysine is adopted as a transfection medium and is incubated together with the cell through a labeled liquid containing superparamagnetic iron oxide-polylysine, and the method comprises the following steps of: 1. preparation of the labeled liquid; 2. cultivation of the human pancreas cancer cell strain; and 3. labeling of the human pancreas cancer cell strain. The superparamagnetic iron oxide labeled human pancreas cancer cell strain can be applied to magnetic resonance imaging and applied to constructing a pancreas cancer animal model.

The invention discloses a pyridine compound containing adamantane substituent groups, and applications thereof in preparation of anti-tumor drugs. The structure for the pyridine compound is represented by formula I, wherein R1, R2, R3, and R4 are independently selected from H, F, or CH3. It is shown by pharmacological results that the pyridine compound possesses MNK1 kinases inhibition effects, wherein the IC50 of JMNK-N002 to JMNK-N005 on MNK1 kinases inhibition activity is 100nM. The pyridine compound possesses relatively in vitro inhibition activity on human pancreatic cancer cell line MiaPaCa2. It is confirmed that the pyridine compound can be used in study on anti-cancer drugs.

The invention discloses application of CD82 / TIMP1 in preparation of medicine for inhibiting migration of human pancreatic cancer cells, and belongs to the technical field of biological engineering. CD82 and TIMP1 are directly combined to trigger the intracellular transport and circulation of TIMP1, block cytoskeleton remodeling, reduce lamellipodia / filopodia projecting formation and inhibit cell viability and migration. TIMP1 enhances an Akt signaling pathway by CD82 on a pancreatic cancer cell membrane, blocks cytoskeleton remodeling, reduces lamellipodia / filopodia projecting formation, inhibits cell viability and migration, and has no effect on the growth of cancer cells. The deep explanation on a TIMP1 / CD82 axis as a new signaling pathway for inhibiting tumor metastasis helps us more clearly know and understand the process of cancer metastasis, and helps find a critical juncture of prevention and control of cancer metastasis.